| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Over the last 12 months, insiders at Armata Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Armata Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Armata Pharmaceuticals, Inc. have bought $34.5M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,385,208 shares for transaction amount of $26.93M was made by Innoviva Strategic Opportunities LLC () on 2022‑03‑31.
| 2022-03-31 | Innoviva Strategic Opportunities LLC | 5.39M 15.2956% | $5.00 | $26.93M | -26.79% | |||
| 2022-02-09 | Innoviva, Inc. | director | 3.61M 12.27% | $5.00 | $18.07M | -21.85% | ||
| 2021-10-29 | Innoviva, Inc. | 1.21M 5.1858% | $3.30 | $4M | +33.75% | |||
| 2021-03-17 | Innoviva, Inc. | 4.29M 12.3568% | $3.25 | $13.93M | -25.41% | |||
| 2021-01-26 | Innoviva, Inc. | 1.87M 8.1521% | $3.25 | $6.07M | +13.46% | |||
| 2020-03-27 | Innoviva, Inc. | 10 percent owner | 7.72M 66.226% | $2.87 | $22.15M | +7.19% | ||
| 2018-03-22 | PERRY MICHAEL S | director | 181,820 1.2965% | $1.10 | $200,002 | -16.38% | ||
| 2018-03-22 | COOK JEREMY CURNOCK | director | 181,820 1.2965% | $1.10 | $200,002 | -16.38% | ||
| 2017-09-19 | PERRY MICHAEL S | director | 105,015 – | $0 | $0 | +11.11% | ||
| 2017-09-19 | COOK JEREMY CURNOCK | director | 105,015 – | $0 | $0 | +11.11% | ||
| 2017-06-29 | PERRY MICHAEL S | director | 5,757 – | $0 | $0 | +43.42% | ||
| 2017-06-29 | COOK JEREMY CURNOCK | director | 5,757 – | $0 | $0 | +43.42% | ||
| 2016-12-29 | Sale | KIRK RANDAL J | 10 percent owner | 42,000 0.3166% | $0.45 | $18,900 | -76.14% | |
| 2016-12-28 | Sale | KIRK RANDAL J | 10 percent owner | 84,620 0.6272% | $0.47 | $39,771 | -77.53% | |
| 2016-12-27 | Sale | KIRK RANDAL J | 10 percent owner | 50,400 0.3723% | $0.51 | $25,704 | -79.36% | |
| 2016-11-22 | COOK JEREMY CURNOCK | director | 46,666 4.0827% | $7.40 | $345,328 | -81.77% | ||
| 2016-06-21 | COOK JEREMY CURNOCK | director | 15,057 – | $0 | $0 | -70.18% | ||
| 2016-04-08 | COOK JEREMY CURNOCK | director | 171,298 – | $0 | $0 | -61.41% | ||
| 2015-10-06 | DRAPEAU LOUIS | director | 10,000 0.1764% | $4.39 | $43,900 | -31.52% | ||
| 2015-10-05 | Salka Michael Scott | Chief Executive Officer | 4,200 0.0834% | $4.75 | $19,950 | -28.73% |
| Innoviva Strategic Opportunities LLC | 16365969 45.218% | $36.82M | 1 | 0 | <0.0001% | |
| BIOGEN IDEC INC | 10 percent owner | 11704095 32.3376% | $26.33M | 1 | 23 | |
| ELAN CORP PLC | 10 percent owner | 11626282 32.1226% | $26.16M | 1 | 3 | |
| Innoviva, Inc. | director | 10980761 30.339% | $24.71M | 5 | 0 | +1.43% |
| KIRK RANDAL J | 10 percent owner | 674169 1.8627% | $1.52M | 1 | 3 | |
| COOK JEREMY CURNOCK | director | 411105 1.1359% | $924,986.25 | 7 | 0 | <0.0001% |
| PERRY MICHAEL S | director | 411105 1.1359% | $924,986.25 | 3 | 0 | <0.0001% |
| PARKER H STEWART | President & CEO | 31175 0.0861% | $70,143.75 | 1 | 0 | |
| DRAPEAU LOUIS | director | 10000 0.0276% | $22,500.00 | 1 | 0 | |
| Salka Michael Scott | Chief Executive Officer | 4200 0.0116% | $9,450.00 | 1 | 0 | |
| Johnson Wendy S. | Interim Chief Operating Office | 1000 0.0028% | $2,250.00 | 1 | 0 | |
| MARXE AUSTIN W & GREENHOUSE DAVID M | 10 percent owner | 0 0% | $0 | 0 | 15 |
$4,968,419 | 139 | 5.13% | $84.03M | |
$2,600,095 | 110 | 13.50% | $74.74M | |
$49,091,668 | 110 | 13.11% | $92.63M | |
$22,608,361 | 93 | 3.94% | $81.65M | |
$4,898,715 | 46 | 40.75% | $78.12M | |
$671,363 | 44 | -16.23% | $77.03M | |
$909,129 | 37 | 42.19% | $85.73M | |
$53,912,175 | 35 | -8.02% | $84.08M | |
$7,147,964 | 34 | 24.78% | $87.83M | |
$36,079,815 | 31 | 43.23% | $93.29M | |
$111,692,551 | 18 | 13.51% | $77.45M | |
$17,567,343 | 12 | 34.87% | $74.96M | |
$135,589,307 | 10 | 32.46% | $92.1M | |
$15,724,108 | 9 | 124.63% | $75.71M | |
Armata Pharmaceuticals, Inc. (ARMP) | $91,549,696 | 8 | -6.55% | $81.44M |
$20,729,984 | 5 | 51.71% | $75.99M | |
$4,256,958 | 4 | 22.95% | $74.83M | |
$18,186,879 | 4 | 49.41% | $75.91M | |
$401,951 | 4 | 57.41% | $90.55M |
| Increased Positions | 4 | +12.5% | 47,064 | +3.39% |
| Decreased Positions | 10 | -31.25% | 695,656 | -50.08% |
| New Positions | 2 | New | 20,951 | New |
| Sold Out Positions | <1 | Sold Out | 136 | Sold Out |
| Total Postitions | 26 | -18.75% | 740,370 | -46.7% |
| Bank Of America Corp /De/ | $911.00 | 1.76% | 634,032 | -15 | <0.01% | 2024-12-31 |
| Vanguard Group Inc | $336.00 | 0.65% | 234,119 | +8,832 | +3.92% | 2024-12-31 |
| Geode Capital Management, Llc | $153.00 | 0.3% | 106,789 | -277 | -0.26% | 2024-12-31 |
| Edgewood Management Llc | $144.00 | 0.28% | 100,000 | 0 | 0% | 2024-12-31 |
| Bridgeway Capital Management, Llc | $100.00 | 0.19% | 69,682 | -5,700 | -7.56% | 2024-12-31 |
| Susquehanna International Group, Llp | $72.00 | 0.14% | 49,788 | +20,002 | +67.15% | 2024-12-31 |
| State Street Corp | $58.00 | 0.11% | 40,300 | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $58.00 | 0.11% | 40,291 | -6,205 | -13.35% | 2024-12-31 |
| Seacrest Wealth Management, Llc | $50.00 | 0.1% | 34,954 | 0 | 0% | 2025-03-31 |
| Blackrock, Inc. | $33.00 | 0.06% | 23,184 | -441 | -1.87% | 2025-03-31 |